By Fineline Cube 
China-based Youcare Pharmaceutical Group (SHA: 688658) announced on July 24, 2025, that its subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (Youcare Pharmaceutical Group Research Centre), has received an Investigational New Drug (IND) approval letter (IND#: 176571) from the U.S. FDA for its self-developed Class 1 new drug, YKYY029 injection. The drug is intended for the treatment of hypertension.
Innovative siRNA Drug
YKYY029 is a small interfering RNA (siRNA) drug targeting the AGT gene, featuring a novel sequence. It leverages Youcare Pharma’s proprietary siRNA modification template and GalNAc delivery system. The company holds exclusive global rights to this innovative technology.
Clinical Progress
Previously, YKYY029 received clinical trial approval from China’s National Medical Products Administration (NMPA). Research findings related to the drug have been published in the journal Molecular Therapy Nucleic Acids, highlighting its potential as a novel therapeutic option for hypertension.-Fineline Info & Tech